Brief: Newcelx Submits Pre-IND Package To FDA For NCEL-101 For Treatment Of Type 1 Diabetes
Brief: Newcelx Updates Corporate Presentation To Highlight Type 1 Diabetes Flagship Program
U.S. STOCKS ON THE MOVE-Eli Lilly, Space stocks, Anixa Biosciences
U.S. STOCKS ON THE MOVE-Intel, Tempus AI, Boeing
U.S. STOCKS ON THE MOVE-Cal-Maine, Rivian, Alkermes
NewcelX rises after raising funds at premium to boost diabetes program
Brief: NewcelX Announces Strategic Collaboration with Eledon Pharmaceuticals to Advance NCEL-101 Program for Type 1 Diabetes
Brief: NewceIX CEO Issues Letter To Shareholders
Brief: NLS Pharmaceutics Ltd. And Kadimastem Ltd. Announce Completion Of Merger
Brief: Nls Pharmaceutics Announces 1-for-10 Reverse Share Split And Name Change In Connection With Proposed Merger With Kadimastem
Brief: NLS Pharmaceutics Shareholders Approve Merger with Kadimastem and Related Proposals at Extraordinary General Meeting
Brief: Kadimastem, NLS Pharmaceutics Announce Effectiveness Of SEC Registration Statement For Proposed Merger
Swiss stocks - Factors to watch on September 1
Brief: NLS Pharmaceutics AG Agreed To Extend Merger Agreement Termination Date With Kadimastem From Aug 31 To Oct 31
Brief: Kadimastem - Total Proceeds From Equity Financing Reach $3 Million
Brief: Nls Pharmaceutics Announces Positive Results From Study Ko-943 Demonstrating Mazindol Reduces Fentanyl-Induced Reward In Animal Models
Brief: NLS Pharmaceutics And Kadimastem Unveil Multi-Target Approach To Diabetes
Brief: NlS Pharmaceutics Ltd Regains Full Compliance With Nasdaq Listing Requirements
Brief: Nls Pharmaceutics AG Regained Compliance With Nasdaq's Minimum Bid Price Requirement